FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097552783> ?p ?o ?g. }

• W3097552783 endingPage "2" @default.
• W3097552783 startingPage "1" @default.
• W3097552783 abstract "Background: Results of the phase III QUAZAR trial suggest that post-remission treatment with an oral form (CC-486) of azacitidine (AZA) can prolong CR duration and overall survival(OS) in AML patients reaching at least PR with intensive chemotherapy (IC) (Wei et al, ASH 2019). Maintenance treatment with subcutaneous (SC) AZA was recently shown to improve DFS in elderly AML (Huls et al, Blood 2019, a study that also included 10% MDS). We report very long term results of a study evaluating SC AZA as post-remission treatment in patients with AML post-MDS or high-risk MDS (HR-MDS) who achieved at least PR after IC, a population known to have short responses with IC. Methods: Inclusion criteria were (1) HR-MDS according to IPSS, or AML after a documented phase of MDS(2) who entered CR, CRi or PR after IC with anthracycline and AraC within 28 days of inclusion (3) ECOG &lt;= 2, absence of infection or organ toxicity from IC (4) no identified donor for allo SCT at inclusion. Dosing of SC AZA was 60mg/m2/d for 5 days every 28 days, with adjustments according to tolerance, and until relapse or toxicity. Results: From July 2006 to June 2009, 51 pts (M:31/F:20) were included. The 46 evaluable pts had achieved CR (n=28), CRi (n=11), and PR (n=7) before study entry. Median age was 66y (range 55-78). Diagnosis at IC onset was MDS (n=13) and AML (n=33), IPSS cytogenetics was normal (n= 28), intermediate (n=10), high (n= 6), and failed (n=2). Median time from diagnosis of MDS to IC was 8 months (range 0.5-101). Median number of AZA maintenance cycles was 7.5 (1-76) in CR pts (&gt;23 cycles in 5 of them) and 4.5 (1-24) in CRi or PR pts (&gt; 23 cycles in 1). Two patients were allografted and censored at allo SCT. Median follow-up was 16.5 months As of May 2020 (cut off date of analysis) median DFS and OS from response were 6.9 m and 16.9 m, respectively (figure). In CR patients, median and 18 months OS were 18.9 months and 58%, versus 12.8 months and 50% in CRi-PR patients (p=0.33) All non allografted patients eventually relapsed. 7 had a response duration &gt;18 months (6 CR patients: 22, 23, 25, 36, 40, and 84 months; 1 CRi patient: 24 months) OS from inclusion was &gt;3 years in 7 patients (CR pts: 150, 126,74, 51, 50,40 months; CRi pt:58 months), in addition to the 2 allografted pts who remained alive in CR at 156+ and 159+ months No baseline factor including cytogenetics, diagnosis at IC onset (MDS vs AML), % bone marrow blasts, age or time from MDS diagnosis to treatment, significantly predicted DFS or OS. AZA dosing in CR patients was escalated in 9 pts to 75mg/m2/d due to good tolerance but had to be reduced in 6 pts, due to GI toxicity (n=1) and cytopenias (n=5). During SC AZA maintenance, 2/28 CR pts developed febrile neutropenia, compared to 4/18 pts in CRi or PR (including 1 fatal case). In the 22 AML post MDS pts who reached CR, DFS and OS were similar to those observed in 46 AML post AML pts included in a previous ALFA study where pts in CR after IC received DNR/IDA-AraC post-remission therapy (Gardin, Blood 2007). Conclusion: In the very long term analysis of this trial in AML post MDS and HR-MDS treated with induction intensive chemotherapy, post-remission therapy with SC AZA alone was associated with a median DFS and OS of 6.9 and 16.9 months, respectively, with some prolonged response. Results appeared similar to those we had reported with intensive consolidation chemotherapy, but using an ambulatory treatment with limited myelosuppression. Figure Disclosures Braun: Daiichy-Sankyo: Honoraria; Servier: Research Funding. Bouabdallah:Takeda: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Gilead Sciences: Consultancy, Honoraria. Ades:Celgene/BMS: Research Funding; novartis: Research Funding; takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; jazz: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding. Fenaux:Abbvie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Jazz: Honoraria, Research Funding." @default.
• W3097552783 created "2020-11-09" @default.
• W3097552783 creator A5000436961 @default.
• W3097552783 creator A5001596576 @default.
• W3097552783 creator A5003572390 @default.
• W3097552783 creator A5005665639 @default.
• W3097552783 creator A5007750346 @default.
• W3097552783 creator A5014838075 @default.
• W3097552783 creator A5020454280 @default.
• W3097552783 creator A5025168447 @default.
• W3097552783 creator A5025598194 @default.
• W3097552783 creator A5029129129 @default.
• W3097552783 creator A5050799774 @default.
• W3097552783 creator A5052673276 @default.
• W3097552783 creator A5053724616 @default.
• W3097552783 creator A5054745373 @default.
• W3097552783 creator A5064103067 @default.
• W3097552783 creator A5068452218 @default.
• W3097552783 creator A5075272745 @default.
• W3097552783 creator A5075950291 @default.
• W3097552783 creator A5078817313 @default.
• W3097552783 creator A5081527133 @default.
• W3097552783 date "2020-11-05" @default.
• W3097552783 modified "2023-10-09" @default.
• W3097552783 title "Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS" @default.
• W3097552783 doi "https://doi.org/10.1182/blood-2020-137012" @default.
• W3097552783 hasPublicationYear "2020" @default.
• W3097552783 type Work @default.
• W3097552783 sameAs 3097552783 @default.
• W3097552783 citedByCount "0" @default.
• W3097552783 crossrefType "journal-article" @default.
• W3097552783 hasAuthorship W3097552783A5000436961 @default.
• W3097552783 hasAuthorship W3097552783A5001596576 @default.
• W3097552783 hasAuthorship W3097552783A5003572390 @default.
• W3097552783 hasAuthorship W3097552783A5005665639 @default.
• W3097552783 hasAuthorship W3097552783A5007750346 @default.
• W3097552783 hasAuthorship W3097552783A5014838075 @default.
• W3097552783 hasAuthorship W3097552783A5020454280 @default.
• W3097552783 hasAuthorship W3097552783A5025168447 @default.
• W3097552783 hasAuthorship W3097552783A5025598194 @default.
• W3097552783 hasAuthorship W3097552783A5029129129 @default.
• W3097552783 hasAuthorship W3097552783A5050799774 @default.
• W3097552783 hasAuthorship W3097552783A5052673276 @default.
• W3097552783 hasAuthorship W3097552783A5053724616 @default.
• W3097552783 hasAuthorship W3097552783A5054745373 @default.
• W3097552783 hasAuthorship W3097552783A5064103067 @default.
• W3097552783 hasAuthorship W3097552783A5068452218 @default.
• W3097552783 hasAuthorship W3097552783A5075272745 @default.
• W3097552783 hasAuthorship W3097552783A5075950291 @default.
• W3097552783 hasAuthorship W3097552783A5078817313 @default.
• W3097552783 hasAuthorship W3097552783A5081527133 @default.
• W3097552783 hasBestOaLocation W30975527831 @default.
• W3097552783 hasConcept C104317684 @default.
• W3097552783 hasConcept C121608353 @default.
• W3097552783 hasConcept C126322002 @default.
• W3097552783 hasConcept C141071460 @default.
• W3097552783 hasConcept C150194340 @default.
• W3097552783 hasConcept C185592680 @default.
• W3097552783 hasConcept C190727270 @default.
• W3097552783 hasConcept C2776239401 @default.
• W3097552783 hasConcept C2776694085 @default.
• W3097552783 hasConcept C2776802502 @default.
• W3097552783 hasConcept C2777063308 @default.
• W3097552783 hasConcept C2778336483 @default.
• W3097552783 hasConcept C2780007613 @default.
• W3097552783 hasConcept C2780817109 @default.
• W3097552783 hasConcept C2908647359 @default.
• W3097552783 hasConcept C29730261 @default.
• W3097552783 hasConcept C31760486 @default.
• W3097552783 hasConcept C530470458 @default.
• W3097552783 hasConcept C55493867 @default.
• W3097552783 hasConcept C71924100 @default.
• W3097552783 hasConcept C90924648 @default.
• W3097552783 hasConcept C99454951 @default.
• W3097552783 hasConceptScore W3097552783C104317684 @default.
• W3097552783 hasConceptScore W3097552783C121608353 @default.
• W3097552783 hasConceptScore W3097552783C126322002 @default.
• W3097552783 hasConceptScore W3097552783C141071460 @default.
• W3097552783 hasConceptScore W3097552783C150194340 @default.
• W3097552783 hasConceptScore W3097552783C185592680 @default.
• W3097552783 hasConceptScore W3097552783C190727270 @default.
• W3097552783 hasConceptScore W3097552783C2776239401 @default.
• W3097552783 hasConceptScore W3097552783C2776694085 @default.
• W3097552783 hasConceptScore W3097552783C2776802502 @default.
• W3097552783 hasConceptScore W3097552783C2777063308 @default.
• W3097552783 hasConceptScore W3097552783C2778336483 @default.
• W3097552783 hasConceptScore W3097552783C2780007613 @default.
• W3097552783 hasConceptScore W3097552783C2780817109 @default.
• W3097552783 hasConceptScore W3097552783C2908647359 @default.
• W3097552783 hasConceptScore W3097552783C29730261 @default.
• W3097552783 hasConceptScore W3097552783C31760486 @default.
• W3097552783 hasConceptScore W3097552783C530470458 @default.
• W3097552783 hasConceptScore W3097552783C55493867 @default.
• W3097552783 hasConceptScore W3097552783C71924100 @default.
• W3097552783 hasConceptScore W3097552783C90924648 @default.
• W3097552783 hasConceptScore W3097552783C99454951 @default.
• W3097552783 hasIssue "Supplement 1" @default.
• W3097552783 hasLocation W30975527831 @default.

• next